SCHEMBL10162863

SCHEMBL10162863

CC(=O)c1ccccc1CNC(=O)c1cc(C(=O)NCc2ccc3oc(=O)n(C)c3c2)nc2ccnn12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.38
MAPT P10636 6/20 0.38
ALOX15 P16050 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
MAPK1 P28482 2/20 0.38
METTL3 Q86U44 1/20 0.37
METTL14 Q9HCE5 1/20 0.37
ADAMTS4 O75173 1/20 0.37
MMP3 P08254 1/20 0.37
MMP8 P22894 1/20 0.37
MMP12 P39900 1/20 0.37
MMP13 P45452 1/20 0.37
SMN1; SMN2 Q16637 7/20 0.37
TP53 P04637 6/20 0.37
KDM4E B2RXH2 5/20 0.37
LMNA P02545 5/20 0.37
HPGD P15428 5/20 0.37
HTT P42858 1/20 0.37
THRB P10828 2/20 0.37
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10208198 0.93 ALDH1A1 (0.38) ALDH1A1MAPTALOX15L3MBTL1MAPK1
SCHEMBL10162851 0.90 MAPT (0.47) ALDH1A1MAPTALOX15L3MBTL1MAPK1
SCHEMBL10162873 0.89 TP53 (0.44) ALDH1A1MAPTALOX15L3MBTL1METTL3
SCHEMBL10162857 0.88 MMP13 (0.39) ALDH1A1MAPTALOX15L3MBTL1METTL3
SCHEMBL10162855 0.88 MMP13 (0.39) ALDH1A1MAPTALOX15L3MBTL1METTL3
SCHEMBL10162862 0.88 TP53 (0.40) ALDH1A1MAPTALOX15L3MBTL1METTL3
SCHEMBL10162853 0.87 POLB (0.39) ALDH1A1MAPTALOX15L3MBTL1METTL3
SCHEMBL10163489 0.87 MMP13 (0.41) ALDH1A1MAPTALOX15L3MBTL1MAPK1
SCHEMBL8225302 0.87 HPGD (0.40) ALDH1A1MAPTALOX15L3MBTL1MAPK1
SCHEMBL8225381 0.86 HPGD (0.49) ALDH1A1MAPK1SMN1; SMN2TP53KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835441-B2 Heterobicyclic metalloprotease inhibitors AMGEN INC. (US) 2014-09-16 US disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 US disclosed
US-7795245-B2 Heterobicyclic metalloprotease inhibitors Atlantos Pharmaceuticals Holding, Inc. (US) 2010-09-14 US disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 US disclosed
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2009-05-28 US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors MMP13, TIMP3, MMP3 ALDH1A1 1806/4885MAPT 3533/4885ALOX15 768/4885
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS MMP13, TIMP3, MMP3 ALDH1A1 1806/4885MAPT 3533/4885ALOX15 768/4885
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 ALDH1A1 1806/4885MAPT 3533/4885ALOX15 768/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 ALDH1A1 1806/4885MAPT 3533/4885ALOX15 768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.